Second-generation drugs, e.g., dasatinib, nilotinib, and bosutinib, that inhibit the tyrosine activity of the BCR-ABLp220 protein are the main line treatment for CML and are used also to maintain remission. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.